Hyperion DeFi (NASDAQ:HYPD – Get Free Report) had its price objective increased by analysts at Chardan Capital from $7.30 to $8.45 in a research note issued on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Chardan Capital’s price target would suggest a potential upside of 132.97% from the stock’s previous close.
HYPD has been the subject of several other research reports. Zacks Research lowered Hyperion DeFi from a “hold” rating to a “strong sell” rating in a report on Wednesday, August 12th. Weiss Ratings raised Hyperion DeFi from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, September 1st. Finally, Cantor Fitzgerald raised their price target on Hyperion DeFi from $6.60 to $7.10 and gave the stock an “overweight” rating in a report on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Hyperion DeFi presently has a consensus rating of “Hold” and an average price target of $7.77.
View Our Latest Report on HYPD
Hyperion DeFi Stock Up 9.9%
Hyperion DeFi (NASDAQ:HYPD – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported $0.92 EPS for the quarter. The company had revenue of $0.36 million during the quarter. Hyperion DeFi had a net margin of 416.56% and a negative return on equity of 11.62%. As a group, equities research analysts forecast that Hyperion DeFi will post 1.78 EPS for the current year.
Hedge Funds Weigh In On Hyperion DeFi
Hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new stake in Hyperion DeFi during the 4th quarter worth about $38,000. Investment House LLC acquired a new position in shares of Hyperion DeFi in the fourth quarter valued at about $166,000. Geode Capital Management LLC purchased a new position in shares of Hyperion DeFi in the fourth quarter worth about $214,000. Focus Partners Advisor Solutions LLC purchased a new position in shares of Hyperion DeFi in the fourth quarter worth about $221,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Hyperion DeFi during the fourth quarter worth about $663,000. 25.84% of the stock is owned by institutional investors and hedge funds.
Hyperion DeFi Company Profile
Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.
Read More
- Five stocks we like better than Hyperion DeFi
- 3 Stocks Built for Higher Rates—And 2 That Could Break
- Safety Stocks Are Not What They Used to Be: 4 Names Built for a Weaker Dollar
- 3 AI Optical Networking Stocks Positioned for the Data Center Buildout
- 5 Defensive Stocks to Watch as CPI and the Fed Put the Rally to the Test
Receive News & Ratings for Hyperion DeFi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hyperion DeFi and related companies with MarketBeat.com's FREE daily email newsletter.
